EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Laser interstitial thermal therapy for recurrent glioblastomas: a systematic review and meta-analysis

Xuzhe Zhao, Runting Li, Yiding Guo, Haibin Wan, Dabiao Zhou

Neurosurgical Review · 16.04.2024 · 47 (1)

DOI: 10.1007/s10143-024-02409-w ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Neurosurgical Review, online erschienen am 16.04.2024. Verfasst von Xuzhe Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, #119 Fanyang Road, Fengtai District, Beijing, 100070, China. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Neoplasm Recurrence, Local, Laser Therapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aim to investigate the efficacy and safety of laser interstitial thermal therapy (LITT) in treating recurrent glioblastomas (rGBMs). A comprehensive search was conducted in four databases to identify studies published between January 2001 and June 2022 that reported prognosis information of rGBM patients treated with LITT as the primary therapy. The primary outcomes of interest were progression-free survival (PFS) and overall survival (OS) at 6 and 12 months after LITT intervention. Adverse events and complications were also evaluated. Eight eligible non-comparative studies comprising 128 patients were included in the analysis. Seven studies involving 120 patients provided data for the analysis of PFS. The pooled PFS rate at 6 months after LITT was 25% (95% CI 15-37%, I2 = 53%), and at 12 months, it was 9% (95% CI 4-15%, I2 = 24%). OS analysis was performed on 54 patients from six studies, with an OS rate of 92% (95% CI 84-100%, I2 = 0%) at 6 months and 42% (95% CI 13-73%, I2 = 67%) at 12 months after LITT. LITT demonstrates a favorable safety profile with low complication rates and promising tumor control and overall survival rates in patients with rGBMs. Tumor volume and performance status are important factors that may influence the effectiveness of LITT in selected patients. Additionally, the combination of LITT with immune-based therapy holds promise. Further well-designed clinical trials are needed to expand the application of LITT in glioma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsNeoplasm Recurrence, LocalLaser TherapyHumansTreatment OutcomeProgression-Free Survival

Stichwörter der Autor:innen

GlioblastomaLaser interstitial thermal therapyLiterature reviewRecurrenceSurvival

Autor:innen und Institutionen

  • Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, #119 Fanyang Road, Fengtai District, Beijing, 100070, China.
  • Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, #119 Fanyang Road, Fengtai District, Beijing, 100070, China. dabiaozhou@163.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhao, X., Li, R., Guo, Y., Wan, H., & Zhou, D. (2024). Laser interstitial thermal therapy for recurrent glioblastomas: a systematic review and meta-analysis. Neurosurgical Review, 47(1). https://doi.org/10.1007/s10143-024-02409-w

Vancouver

Zhao X, Li R, Guo Y, Wan H, Zhou D. Laser interstitial thermal therapy for recurrent glioblastomas: a systematic review and meta-analysis. Neurosurgical Review. 2024;47(1). doi:10.1007/s10143-024-02409-w

BibTeX
@article{Zhao2024,
  author = {Zhao, Xuzhe and Li, Runting and Guo, Yiding and Wan, Haibin and Zhou, Dabiao},
  title = {Laser interstitial thermal therapy for recurrent glioblastomas: a systematic review and meta-analysis},
  journal = {Neurosurgical Review},
  year = {2024},
  volume = {47},
  number = {1},
  doi = {10.1007/s10143-024-02409-w}
}
Kostenlos starten →